PMID- 24194771
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20220318
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2013
DP  - 2013
TI  - Combination with methotrexate and cyclophosphamide attenuated maturation of 
      dendritic cells: inducing Treg skewing and Th17 suppression in vivo.
PG  - 238035
LID - 10.1155/2013/238035 [doi]
LID - 238035
AB  - Immune disorder is considered the main pathogenesis of autoimmune diseases, such 
      as rheumatoid arthritis (RA). The balance of the two special subsets of CD4(+)T 
      cells, T helper cell 17 (Th17), and Regulator T cell (Treg) is the key factor of 
      maintaining a normal immune response. Dendritic cells (DCs), which are the most 
      powerful antigen-presenting cells, play an important role in regulating the 
      balance of Th17 and Treg. The combination of disease modifying antirheumatic 
      drugs (DMARDs) is an important strategy of RA therapy. In this study, we 
      investigated the effect of MTX and CTX on DC maturation in ovalbumin (OVA) 
      immunized mice. Th17 inflammatory response is stronger, while the level of DCs 
      maturity is higher. In contrast, the immunosuppression of Treg is stronger. We 
      found that MTX combined with CTX significantly inhibited the DCs maturity and 
      downregulated the antigen presenting capacity of DCs. As a result, it 
      reestablished a balance of Th17 and Treg. Our study adds a novel mechanism and 
      therapeutic target of MTX combined with CTX for autoimmune disease treatment.
FAU - Yu, Xiaoyang
AU  - Yu X
AD  - Department of Rheumatology, The Second Hospital of Shanxi Medical University, 382 
      Wu Yi Road, Taiyuan 030001, China.
FAU - Wang, Caihong
AU  - Wang C
FAU - Luo, Jing
AU  - Luo J
FAU - Zhao, Xiangcong
AU  - Zhao X
FAU - Wang, Lixing
AU  - Wang L
FAU - Li, Xiaofeng
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130930
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Antigens, Surface)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 9006-59-1 (Ovalbumin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Animals
MH  - Antigens, Surface/metabolism
MH  - Cell Differentiation/*drug effects
MH  - Cyclophosphamide/*pharmacology
MH  - Dendritic Cells/*cytology/*drug effects/immunology/metabolism
MH  - Immunophenotyping
MH  - Lymphocyte Activation
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Methotrexate/*pharmacology
MH  - Mice
MH  - Ovalbumin/immunology
MH  - Phenotype
MH  - T-Lymphocytes, Regulatory/drug effects/immunology/metabolism
MH  - Th17 Cells/drug effects/immunology/metabolism
PMC - PMC3806152
EDAT- 2013/11/07 06:00
MHDA- 2014/06/10 06:00
PMCR- 2013/09/30
CRDT- 2013/11/07 06:00
PHST- 2013/05/05 00:00 [received]
PHST- 2013/08/01 00:00 [revised]
PHST- 2013/08/15 00:00 [accepted]
PHST- 2013/11/07 06:00 [entrez]
PHST- 2013/11/07 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
PHST- 2013/09/30 00:00 [pmc-release]
AID - 10.1155/2013/238035 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2013;2013:238035. doi: 10.1155/2013/238035. Epub 2013 Sep 30.